A therapy delayed the onset of Type 1 diabetes in at-risk people by about two years, new results from a clinical trial show.
What happens when a person with prediabetes get a viral infection? New study provides in-depth look
Scientists monitored 106 individuals (some of whom have prediabetes) to see how the condition, and infections, impact immune-and-microbiome-related health.
Promising finding for people with Type 2 diabetes and kidney disease
Results from a multi-center clinical trial show that a drug lowers the risk of kidney failure by a third in people with Type 2 diabetes and kidney disease.
Type 1 diabetes: Developing an early warning system
Type 1 diabetes starts out as a sneak attack by bad-actor antibodies. But scientists at Stanford and UCSF have developed an early-warning system.
Zinc chelation may be able to deliver drug to insulin-producing cells
By delivering a drug directly to beta cells, researchers may be able to spur insulin production and potentially develop a diabetes therapy in the future.
With rising demand for insulin, half of those in need will lack access in 2030, new study suggests
Access and cost of insulin is affecting those who need it most, and without major improvements, millions will be without a treatment, a new study suggests.
Genetics of cholesterol reveal insights into heart disease and diabetes drug targets
Scientists find new potential drug targets for heart disease and diabetes, while shedding more light on the genetics of cholesterol, a new study has found.
Insulin resistance affects the kidneys, Stanford study finds
Although pioneering scientist Gerald Reaven thought that insulin resistance did not affect the kidney, new research suggests that the story is more complex.
Successful diabetes management program brings down cost of care
A diabetes program, developed with a Stanford scientist, helps cut costs of diabetes-related health care expenses by $815 per year per person.
Disrupt Diabetes draws patients into innovation process
A design challenge called Disrupt Diabetes was created and spearheaded by two Stanford seniors — best friends and aspiring doctors who felt that innovations for people with diabetes should bubble up from patients’ daily experiences and priorities.
A look at Stanford’s personalized, team-based approach to diabetes
This video highlights Stanford Health Care's team-based approach to diabetes care. Patient Hazel shares her experience helping to design a treatment plan.
Breaking down diabetes: New controversy on blood sugar lowering
In this final installment of the "Breaking down diabetes" series, physician-researcher Randall Stafford weighs in on a debate about blood sugar levels that relates to drug prices.
Breaking down diabetes: Insulin, unwelcome, but underutilized
In this Breaking Down Diabetes installment, physician-research Randall Stafford clarifies the pros and cons of insulin use in Type 2 diabetes.
Breaking down diabetes: How to prevent complications
This is the fifth in a series of blog posts, by Randall Stafford, MD, PhD discussing prediabetes and Type 2 diabetes.
Breaking down diabetes: The importance of complications
Diabetes itself has few symptoms, but its consequences can lead to disability and death. Stanford's Randall Stafford breaks down complications.
Breaking down diabetes: Top priorities for patients and their doctors
This is the third in a series of blog posts by Randall Stafford, MD, PhD, discussing prediabetes and Type 2 diabetes.